Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CrisprPr: a hybrid-driven framework for CRISPR/Cas9 off-target prediction with analysis of prior-information updates.

Briefings in bioinformatics·2026
Same author

Correction: N6‑methyladenosine‑modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14‑dependent manner in renal cell carcinoma.

Molecular cancer·2026
Same author

ProTCR: a protein language model-driven framework for decoding TCR-antigen recognition toward precision immunotherapies.

Briefings in bioinformatics·2026
Same author

Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Benchmarking algorithms for generalizable single-cell perturbation response prediction.

Nature methods·2025
Same author

Utility of a novel and cost-effective biological model for percutaneous renal access training.

Translational andrology and urology·2025

Related Experiment Video

Updated: Sep 13, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine.

Xudong Mao1, Zhehao Xu1, Xingbo Yang2

  • 1Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Cancer Research
|July 29, 2025
PubMed
Summary
This summary is machine-generated.

N6-methyladenosine (m6A) dysregulation significantly reduces tumor survival. This study introduces a causal framework to identify personalized anti-m6A therapies, highlighting the PI3K/AKT/mTOR pathway for targeted treatment strategies.

More Related Videos

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
05:58

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Published on: August 16, 2024

3.1K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Related Experiment Videos

Last Updated: Sep 13, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
05:58

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Published on: August 16, 2024

3.1K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • N6-methyladenosine (m6A) modifications regulate gene expression and transcript metabolism, influencing cancer progression.
  • Dysregulation of m6A is implicated in various malignancies, necessitating methods to quantify its population-level impact.

Purpose of the Study:

  • To develop a causal framework for estimating the driving effects (DE) of m6A dysregulation on tumor survival.
  • To establish DE-based rules for prioritizing anti-m6A therapies.
  • To identify patient subgroups and molecular pathways that modify the impact of m6A dysregulation.

Main Methods:

  • Development of a causal framework to estimate the driving effects (DE) of m6A dysregulation.
  • Analysis of m6A dysregulation impact on overall survival across 9,647 tumors.
  • Profiling of tumors susceptible to m6A dysregulation.
  • Application of a modifier-mining tool to identify pathway interactions.
  • In vitro and in vivo validation of identified effect modifications.

Main Results:

  • Global average DE of m6A dysregulation was associated with a 180.1-day decrease in overall survival (5-year endpoint).
  • The PI3K/AKT/mTOR pathway was identified as a key modifier of m6A dysregulation effects.
  • Treatment benefits of targeting m6A were found to be dependent on baseline mTOR levels, confirmed by experimental validation.

Conclusions:

  • A novel causal framework effectively quantifies the impact of m6A dysregulation on tumor survival.
  • Leveraging DE provides a paradigm for optimizing personalized anti-m6A therapies.
  • Targeting m6A in conjunction with modulating pathways like PI3K/AKT/mTOR, particularly mTOR levels, offers a promising personalized therapeutic strategy.